Cortexyme publishes data on P. gingivalis ability to infect neurons
Cortexyme, Inc., a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer's (AD) and other degenerative diseases, ...